Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Presenilin enhancer protein 2–lysosomal vacuolar-type H+-ATPase complex is a multi-protein assembly that serves as a pivotal hub for cellular energy sensing and lysosomal maintenance [1]. Presenilin enhancer 2 (PEN-2), traditionally recognized as a core subunit of the gamma-secretase complex, has been recently identified as a direct sensor for glucose on the lysosomal membrane [2]. Under conditions of glucose starvation, the absence of glucose binding allows PEN-2 to interact with the ATP6V1A subunit of the vacuolar-type H+-ATPase (v-ATPase), which triggers the recruitment of the AXIN-LKB1 complex to activate AMP-activated protein kinase (AMPK) [1, 4]. Beyond its role in metabolic signaling, this complex is essential for maintaining the acidic environment of the lysosome, which is required for the degradation of cellular waste via autophagy [2]. Impairment of the PEN-2–v-ATPase interaction is linked to the pathogenesis of Alzheimer's disease, as it leads to lysosomal alkalization and the accumulation of amyloid-beta and tau aggregates [3]. Consequently, this complex represents a novel therapeutic target for both metabolic diseases and neurodegeneration, offering a mechanism to modulate energy balance and enhance proteostatic clearance [1, 4].
Glucose-dependent recruitment of the AXIN-LKB1 complex to the v-ATPase for AMPK activation and regulation of lysosomal pH.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Presenilin enhancer protein 2–lysosomal vacuolar-type H+-ATPase complex (PEN-2–v-ATPase).